Rein Therapeutics Files 8-K with Corporate Updates
Ticker: RNTX · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing, bylaws
TL;DR
Rein Therapeutics filed an 8-K on Jan 10, 2025, with corporate updates and exhibits.
AI Summary
Rein Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting an amendment to its articles of incorporation or bylaws, other events, and financial statements/exhibits. The company, formerly known as Aileron Therapeutics, Inc. until March 29, 2024, is based in Austin, Texas.
Why It Matters
This filing indicates potential corporate restructuring or significant operational updates for Rein Therapeutics, Inc., which could impact its strategic direction and investor outlook.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information about significant financial distress or major operational changes that would inherently increase risk.
Key Numbers
- 001-38130 — SEC File Number (Identifies the company's filing with the SEC)
- 13-4196017 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- Aileron Therapeutics, Inc. (company) — Former company name
- January 10, 2025 (date) — Date of earliest event reported
- March 29, 2024 (date) — Date of name change from Aileron Therapeutics, Inc.
- Austin, Texas (location) — Company's business address
FAQ
What specific amendments were made to the articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the summary text.
What are the 'Other Events' being reported?
The filing states 'Other Events' are being reported, but the nature of these events is not detailed in the provided text.
What financial statements and exhibits are included with this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific content of these documents is not described.
When did Rein Therapeutics, Inc. officially change its name from Aileron Therapeutics, Inc.?
The company's name was changed from Aileron Therapeutics, Inc. on March 29, 2024.
What is the company's business address?
The company's business address is 12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758.
Filing Stats: 669 words · 3 min read · ~2 pages · Grade level 9.5 · Accepted 2025-01-10 16:06:34
Key Financial Figures
- $0.001 — nge On which registered Common Stock, $0.001 par value per share RNTX The Nasdaq
Filing Documents
- d898488d8k.htm (8-K) — 28KB
- d898488dex31.htm (EX-3.1) — 5KB
- d898488dex32.htm (EX-3.2) — 109KB
- 0001193125-25-004443.txt ( ) — 289KB
- rntx-20250110.xsd (EX-101.SCH) — 2KB
- rntx-20250110_lab.xml (EX-101.LAB) — 18KB
- rntx-20250110_pre.xml (EX-101.PRE) — 11KB
- d898488d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to Restated Certificate of Incorporation 3.2 Amended and Restated Bylaws 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rein Therapeutics, Inc. Date: January 10, 2025 By: /s/ Brian Windsor Brian Windsor, Ph.D. President and Chief Executive Officer